🇺🇸 FDA
Patent

US 7691895

Thrombopoietin activity modulating compounds and methods

granted A61PA61P21/04A61P25/00

Quick answer

US patent 7691895 (Thrombopoietin activity modulating compounds and methods) held by Ligand Pharmaceuticals Incorporated expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ligand Pharmaceuticals Incorporated
Grant date
Tue Apr 06 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P21/04, A61P25/00, A61P43/00, A61P7/00